Arsenic trioxide-induced cardiotoxicity: the protective effect of 2-aminoethoxydiphenyl-borate
- PMID: 38495004
- PMCID: PMC11090852
- DOI: 10.3724/abbs.2024036
Arsenic trioxide-induced cardiotoxicity: the protective effect of 2-aminoethoxydiphenyl-borate
Conflict of interest statement
The authors declare that they have no conflict of interest.
Figures
References
-
- Jiang Y, Shen X, Zhi F, Wen Z, Gao Y, Xu J, Yang B, et al. An overview of arsenic trioxide-involved combined treatment algorithms for leukemia: basic concepts and clinical implications. Cell Death Discov. . 2023;9:266. doi: 10.1038/s41420-023-01558-z. - DOI - PMC - PubMed
-
- Sönksen M, Kerl K, Bunzen H. Current status and future prospects of nanomedicine for arsenic trioxide delivery to solid tumors. Med Res Rev. . 2022;42:374–398. doi: 10.1002/med.21844. - DOI - PubMed
-
- Pan X, Huang J, Liu S, Shao Y, Xi J, He R, Shi T, et al. pH-responsive and liver-targeting drug delivery system for combination delivery of artesunate with arsenic trioxide prodrug against hepatocellular carcinoma. Drug Dev Industrial Pharmacy. . 2023;49:485–496. doi: 10.1080/03639045.2023.2239342. - DOI - PubMed
-
- Alamolhodaei NS, Shirani K, Karimi G. Arsenic cardiotoxicity: an overview. Environ Toxicol Pharmacol. . 2015;40:1005–1014. doi: 10.1016/j.etap.2015.08.030. - DOI - PubMed
-
- Rosalez M, Estevez-Fregoso E, Alatorre A, Abad-García A, A Soriano-Ursúa M. 2-Aminoethyldiphenyl borinate: a multitarget compound with potential as a drug precursor. Curr Mol Pharmacol. . 2020;13:57–75. doi: 10.2174/1874467212666191025145429. - DOI - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
